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Background: We built the Drug Ontology (DrOn) because we required correct and consistent drug information in
a format for use in semantic web applications, and no existing resource met this requirement or could be altered
to meet it. One of the obstacles we faced when creating DrOn was the difficulty in reusing drug information from
existing sources. The primary external source we have used at this stage in DrOn’s development is RxNorm, a
standard drug terminology curated by the National Library of Medicine (NLM). To build DrOn, we (1) mined data
from historical releases of RxNorm and (2) mapped many RxNorm entities to Chemical Entities of Biological Interest
(ChEBI) classes, pulling relevant information from ChEBI while doing so.
Results: We built DrOn in a modular fashion to facilitate simpler extension and development of the ontology and
to allow reasoning and construction to scale. Classes derived from each source are serialized in separate modules.
For example, the classes in DrOn that are programmatically derived from RxNorm are stored in a separate module
and subsumed by classes in a manually-curated, realist, upper-level module of DrOn with terms such as ‘clinical
drug role’, ‘tablet’, ‘capsule’, etc.
Conclusions: DrOn is a modular, extensible ontology of drug products, their ingredients, and their biological
activity that avoids many of the fundamental flaws found in other, similar artifacts and meets the requirements of
our comparative-effectiveness research use-case.
Keywords: Drug Ontology, RxNorm, ChEBIBackground
Several researchers have identified use cases for an
ontology of drugs, such as comparative effectiveness re-
search [1], clinical decision support [2-4], and clinical
data warehousing and data integration [2,3,5-7], among
others. We previously analyzed existing terminology and
ontology artifacts that represent some aspect of drugs,
and found that no existing resource was sufficient for
our use cases in these domains [8]. Our requirements in-
cluded (1) a historically comprehensive list of NDCs, (2)
correctness with respect to pharmacology and biomed-
ical science, (3) logically consistent, correct axioms that
do not entail untrue or inconsistent inferences, and (4)
interoperability with other ontologies used in transla-
tional science. Specifically, we analyzed RxNorm, the
National Drug File – Reference Terminology, SNOMED
CT, Chemical Entities of Biological Interest (ChEBI), an* Correspondence: jhanna@uams.edu
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reproduction in any medium, provided the orOWL conversion of the Anatomical and Therapeutic
Chemical classification system, DrugBank, PharmGKB,
and other sources and found that none of them met
these requirements. Minimally, no existing resource con-
tains in its current version a historically comprehensive
list of National Drug Codes (NDCs). We also found
problems with scientific correctness and unintended and
incorrect description logic entailments from artifacts
represented in Web Ontology Language. A key flaw in-
herent in several artifacts that frequently led to scientif-
ically incorrect representations of drugs was assigning
the properties of drug products such as tablets, creams,
ointments, etc. to molecules and vice versa.
We therefore decided to build the Drug Ontology
(DrOn) to meet our requirements. However, rather than
assemble comprehensive historical information about
drug products from scratch, we decided to begin with
resources that (1) had enough quality information about
drugs to begin with, (2) could therefore be restructuredLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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allow us to make DrOn publicly available.
RxNorm [5]—a standard drug terminology maintained
by the U.S. National Library of Medicine (NLM)—in-
cludes normalized names and relationships extracted
from several proprietary drug knowledge bases. Because
RxNorm (1) contains a large amount of drug informa-
tion, (2) is freely available, and (3) has a great deal of
content available under a permissive license that allows
derivative works, it is a good candidate for a source of
information to create a formal drug ontology. In particu-
lar, RxNorm had enough information to allow us to rect-
ify numerous shortcomings of existing artifacts, and its
historical versions collectively contain the largest, openly
available set of historical NDCs, dating back until June
2008 at least (the date of the first version of RxNorm to
contain NDCs).
RxNorm is focused primarily on prescription and
over-the-counter drugs that are currently available in the
United States. It uses Concept Unique Identifiers called
RXCUIs to catalog and relate information.
At this stage of DrOn development, we are interested in
the ability to query for historical NDCs to study pharmacy
claims databases that contain a decade or more of data
(and thus NDCs in use 10 years ago as well as today are re-
quired). The NDC is a unique identifier that the Drug List-
ing Act of 1972 requires companies to report to the Food
and Drug Administration (FDA). RxNorm associates each
NDC with a drug product via the RXCUI. Although our re-
quirement is to have a comprehensive, historical list of
NDCs, RxNorm maintains only currently active NDCs in
its current release. So tracking all NDCs and the RXCUIs
with which they have been associated over historical re-
leases of RxNorm is key to building DrOn, and represents a
key contribution of the present work.
Moreover, NDCs are often lost with no explanation when
an RXCUI is retired, especially in releases of RxNorm prior
to 2009. This situation necessitates careful tracking to en-
sure that all valid NDCs (and, indeed, any useful informa-
tion) associated with a retired RXCUI can be associated
with the most recent RXCUI that refers to the same entity.
In this paper, we describe how we build DrOn from his-
torical releases of RxNorm while navigating these pitfalls.
In addition, during the build process, we map drug ingredi-
ents from RxNorm to the Chemical Entities of Biological
Interest (ChEBI) ontology [9]. For example, we map the
RXCUI for furosemide (4603) to the ChEBI identifier
for furosemide: http://purl.obolibrary.org/obo/CHEBI_47426.
As a result, we import hundreds of ChEBI classes and their
associated URIs, labels, etc. into DrOn.
Methods
The overall workflow of the extraction and translation
process has three main steps:1. Extracting relevant data from RxNorm, including
information found only in older releases.
2. Transforming and loading this data into a
normalized Relational Database Management System
(RDBMS).
3. Translating the normalized RDBMS into an OWL
2.0 artifact.
Each of these three steps is further subdivided into
substeps that we explain in detail below.Extracting information from RxNorm
We first download the raw RxNorm files directly from the
NLM website, specifically the UMLS (or Unified Medical
Language System) Terminology Services (UTS) site [10]
and import them into a locally hosted RDBMS using the
scripts provided by the NLM. Additionally, to support
maintenance of comprehensive information over time, we
created and maintain two additional tables that store all the
information that we extract from each release of RxNorm
(a subset of all the information). We describe these tables
in detail below (sections entitled Extraction of National
Drug Codes (NDCs) and related RXCUIs and Tracking
Provenance).
Currently, we include in DrOn information from every
version of RxNorm released between June, 2008 and Febru-
ary, 2013. The release from June, 2008 marks the first time
that RxNorm-curated NDCs were included.
It should be noted that we use only information curated
within RxNorm and not any information from its sources
directly, and thus our overall process is allowable under the
UMLS license (all content reused in DrOn is marked Level
0, which, per the license, does not prohibit derivative works
as do levels 1 and higher).RxNorm files
The next step is to extract all relevant information from
the files downloaded from the UTS site. RxNorm comes
as a set of nine Rich Release Format (RRF) files, each of
which contains a specific subset of the total information.
However, we process only five of these files in our build
process.
Specifically, we process RXNSAT.RRF, RXNCONSO.RRF,
RXNCUI.RRF, RXNCUICHANGES.RRF, and RXNSAB.
RRF. Table 1 shows the information we extract from each
file.
There are four different “term types” in RXNCUI.RRF
that are relevant to DrOn. They are: (1) Semantic Clinical
Drug Forms (SCDFs), (2) Semantic Clinical Drugs (SCDs),
(3) Semantic Branded Drugs (SBDs), and (4) Ingredients
(IN). RxNorm treats NDCs as attributes of an SCD or SBD
rather than a separate term type.
Table 1 The RxNorm files and the information extracted
from each
File Extracted information
RXNSAT.RRF NDCs and RXCUIs
RXNCONSO.RRF SCDFs, SCDs, SBDs, and INs and their RXCUIs
RXNCUI.RRF retired RXCUIs with provenance
RXNCUICHANGES.RRF RXCUI provenance
RXNSAB.RRF RxNorm version information
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Tracking entities within RxNorm requires tracking the
RXCUIs to which they are attached. This can be a diffi-
cult task. Any RXCUIs that have been entered in error
are retired. Additionally, if two RXCUIs refer to the
same entity, they are consolidated and either (1) one of
them is retired while the other remains or (2) a new
RXCUI is created and both older RXCUIs are retired
(Figure 1). Prior to the April 2009 release of RxNorm,
no comprehensive list of retired RXCUIs was included
in RxNorm. The reasons for retirement are not always
well-documented, making it difficult to distinguish be-
tween RXCUIs that have been retired because they are
nonsense and ones that have been replaced or merged.
For instance, as of this writing, there are 40 RXCUIs
with 210 associated NDCs that are no longer contained
in the most recent release of RxNorm, however, there is
no record of why these RXCUIs were removed.
Extraction of National Drug Codes (NDCs) and related
RXCUIs
To facilitate the tracking of NDCs, we have created an
additional table, NDC_COMP, that contains a compre-
hensive list of all RxNorm-curated NDCs from all re-
leases of RxNorm since June 2008 (when they first
appeared) and their corresponding RXCUIs. To generate
this table, we parse the RXNSAT.RRF file in each release
of RxNorm. Any entry in the file whose source is
RxNorm and is annotated as being an NDC is extractedFigure 1 How RXCUIs are de-duplicated. How the National Library of Mfrom the file, along with its associated RXCUI, and
imported into our NDC_COMP table. We also store the
version from which each NDC was mined, which is
parsed from the RXNSAB.RRF file.
Tracking provenance
The second of the two additional tables is a master con-
version table, DEPRECATED_RXCUIS, which we use to
track the current status of each retired RXCUI. This
table contains two fields: old_rxcui and new_rxcui. The
old_rxcui field contains a retired RXCUI, and the new_-
rxcui field contains the current RXCUI to which the re-
tired RXCUI’s information is now associated. The
new_rxcui field may also contain a status code if the
retired RXCUI’s information is unable to be tracked
because it was entered in error or split into multiple
new RXCUIs. These special status codes are “ERROR”
for RXCUIs that have been entered in error and
“S_RXNCUI” for RXCUIs which have been split. Be-
cause RxNorm does not document why an erroneous
RXCUI was entered in error, we are unable to do further
processing on them or their associated information. For
the RXCUIs which are split, it may be possible to track
some of their associated information, but it is not always
clear which information belongs to which child RXCUI
and this issue requires manual intervention at present.
Our DEPRECATED_RXCUIS table is updated with
each release of RxNorm through the following proced-
ure (Figure 2):
1. First, we extract any RXCUIs from the
comprehensive NDC_COMP table, built as
described above (section entitled Extraction of
National Drug Codes (NDCs) and related RXCUIs),
that can no longer be found in the RXNCONSO.
RRF file being imported. We then import these
RXCUIs into the old_rxcui column of our
DEPRECATED_RXCUIS table. Because the
RXNCONSO.RRF file contains all current RXCUIs,edicine handles RXCUI errors within RxNorm.
Figure 2 Workflow for updating the DEPRECATED_RXCUIS table. How we tracked RXCUI provenance.
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been retired.
2. Next, using the RxNorm-curated RXNCUI table, we
update all entries in the new_rxcui column. The
RXNCUI table contains a cui1 field containing a re-
tired RXCUI, a cui2 field containing the RXCUI into
which the retired RXCUI’s information has been
merged, and a cardinality column contains the num-
ber of RXCUIs into which the information has been
merged. Any RXCUI that has been entered in error
is indicated by an entry in which the value of the
cui1 field is equal to the value of the cui2 field. Add-
itionally, any entry with a cardinality greater than 1
indicates that the RXCUI has been split. These are
indicated in our table by setting the new_rxcui entry
to “ERROR” and “S_RXNCUI”, respectively. As of
this writing, 768 RXCUIs and 3,484 associated
NDCs are reported by RxNorm to have been en-
tered in error and are therefore not included in
DrOn. Additionally, 187 RXCUIs and 3,126 associ-
ated NDCs have been split. Both these RXCUIs and
NDCs have also been left out of DrOn (for the time
being) due to the difficulty of determining which in-
formation from the parent RXCUI belongs to which
child RXCUI.
3. Finally, we compute the transitive closure,
associating each RXCUI with the latest RXCUI that
refers to the same entity with no intervening steps
in our DEPRECATED_RXCUIS table. Because this
table is updated with each release of RxNorm,
occasionally an RXCUI in the new_rxcui field is
retired. In such situations, the new_rxcui field is
updated as described in Step 2, and a new row in
the table is created with the newly-retired RXCUI
set as the old_rxcui, and the new_rxcui field is set to
match the updated new_rxcui from the original
entry.
Mapping to ChEBI
The process maps ingredients (IN entity type) extracted
from RxNorm to ChEBI Uniform Resource Identifiers
(URIs) where possible. We accomplish this step through
a simple Java console application (that we built) thatcompares the labels of ingredients pulled from RxNorm
with class annotations in ChEBI. We assumed that any
exact matches between the names or synonyms of
RxNorm IN entities and ChEBI annotations meant that
the RxNorm concept and ChEBI class referred to the
same entity, and thus we used the ChEBI URIs in DrOn
for the ingredient. We used three different annotation
types from ChEBI in the mapping process: rdfs:label,
related_synonym, and exact_synonym. To date, we im-
port into DrOn ~750 classes (including URI and rdfs:
label and other annotations) from ChEBI: roughly 500
matches were on rdfs:label, 250 were on related_syno-
nym, and only two were on exact_synonym. Many of the
ingredients found in RxNorm are extracts of various
plants, e.g. ginger extract, which we would not expect to
find in ChEBI. These ingredients are currently all chil-
dren of the class processed material, which we imported
from the Ontology of Biomedical Investigations (OBI).
The process originally mapped somatropin (also
known as somatotroin or human growth hormone) erro-
neously to the ChEBI role ‘growth hormone’. Once we
noticed this error, we fixed it. The ingredient is now
mapped to the Protein Ontology URI that represents the
protein molecule somatotropin.
We assigned a DrOn URI to every ingredient that was
not found in ChEBI via this process.Transforming the data into a normalized format
As noted above, there are five RxNorm term types that
we were initially interested in pulling from RxNorm, in-
cluding ingredient, clinical drug form, clinical drug,
branded drug, and national drug code (NDC). Addition-
ally, we wanted to represent a number of dispositions of
ingredients, such as the disposition of metoprolol to
bind beta-adrenergic receptors of cells. Figure 3 shows
these six entity types and the relationships between
them. Note that the entities the NDC classes represent
are not the codes themselves, but instead the packaged
drug products that the NDCs represent. Additionally,
every DrOn entity that corresponds to a RxNorm entity
is annotated with the corresponding RXCUI via an an-
notation property called has_Rxcui.
Figure 3 DrOn Entity Types. The entity types of DrOn and their relationships as stored in the normalized format.
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The ingredient entities represent the types of molecules
that are present in a drug product and have an active
biological role. The URIs of ingredients, where possible,
are taken from the Chemical Entities of Biological Inter-
est (ChEBI) ontology as described above. Examples of in-
gredients include acetaminophen, sulfur, and ephedrine.
There are 7,848 unique ingredients in DrOn.
The disposition entities represent dispositions that
molecules bear (see Hogan et al. [8]) that correspond to
what is typically considered a drug’s mechanism of ac-
tion. There are, as of now, six molecular dispositions in
DrOn. They are:
1. non-activating competitive beta-adrenergic receptor
binding disposition (i.e., beta-adrenergic blockade)
2. function-inhibiting hydrogen/potassium adenosine
tri-phosphatase enzyme (H+/K + ATPase) binding
disposition (i.e., proton-pump inhibition)
3. function-inhibiting L-type voltage-gated calcium
channel binding disposition (i.e., the subtype of
calcium-channel blockade found in cardiovacscular
drugs that lower blood pressure and alter heart
rhythm)
4. function-inhibiting vitamin K epoxide reductase
binding disposition (i.e., the type of Vitamin K
antagonism exhibited by warfarin)
5. function-inhibiting Na-K-Cl cotransporter 2 (NKCC2)
binding disposition (i.e., NKCC2 inhibition)
6. function-inhibiting T-type calcium channel binding
disposition (i.e., another subtype of calcium-channel
blockade, which does not have cardiovascular effects)
These six dispositions were chosen based on their bio-
logical importance and relevance to ongoing compara-
tive effectiveness research at the University of Arkansas
for Medical Sciences. There is no direct correspondence
between DrOn dispositions and RxNorm, because bydesign RxNorm lacks information about drugs’ mechan-
ism of action. Instead, the relationships between DrOn
dispositions and ingredients were mined from ChEBI, al-
though ChEBI treats the same realizable entities that we
represent as roles [8]. Table 2 shows the associated ChEBI
role from which the ingredient relationships for the three
dispositions were mined. Authors WRH and JH manually
curated the other three dispositions not in the table.
Function-inhibiting T-type calcium channel binding
disposition was included because we erroneously associ-
ated ethosuximide and function-inhibiting L-type voltage-
gated calcium channel binding disposition. This error
was not due to any particular oversight of ChEBI but an
artifact caused by the more specific nature of DrOn’s
dispositions as compared to ChEBI’s more general cal-
cium channel blocker. Ethosuximide instead is the bearer
of a function-inhibiting T-type voltage-gated calcium
channel binding disposition, which does not confer any
cardiovascular activity but instead gives it a neurological,
anti-seizure activity.
The Clinical Drug Form (CDF) entities represent
types of drug products at the level of granularity of dose
form (e.g. drug tablet) and often the intended route of
administration (e.g. oral ingestion), without brand or
strength information. They correspond with SCDFs in
RxNorm. Examples of CDFs include estradiol transder-
mal patch, iodine topical solution, and menthol crystals.
There are 14,035 unique CDFs in DrOn.
The Clinical Drug (CD) entities represent drug prod-
ucts at the level of granularity of specific dosage/
strength/form information. They are related to the CDF
by an is-a relationship. For example, every aspirin 325
MG enteric coated tablet (CD) is a aspirin enteric coated
tablet (CDF). DrOn contains 34,560 CDs.
The Branded Drug (BD) entities represent brand-
name drug products with specific dosage/strength/form
information. The drug products that BDs represent are
related to the products that CDs represent by an is-a
Table 2 The ChEBI roles used to mine DrOn disposition-
ingredient relationships






adenosine triphosphatase enzyme (H+/K +
ATPase) binding disposition
proton pump inhibitor
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ship, but drug products are not names). There are
21,248 unique BDs in DrOn.
The National Drug Code (NDC) entities represent a
drug product and its packaging, such as a 100 tablet bot-
tle of acetaminophin 325 mg oral tablets. These entities
are distinct from entities represented by BDs or CDs, in-
stead containing some number of instances of drug
products represented by CDs/BDs, for example a 100-
tablet bottle of aspirin 325 mg tablets. There are 390,813
unique NDC entities in DrOn (Table 3).
RDBMS design
The RDBMS design representing the normalized format
of the entity types described above is simple. There are 5
core tables, one for each entity type. These are as fol-
lows: clinical_drug_form, clinical_drug, branded_drug,
ndc, ingredient, and disposition.
Additionally, there are two tables storing provenance in-
formation from RxNorm, such as the version of RxNorm in
which each RxCUI was found. These are rxcui and rxnorm.
These are completely separate from the core entity tables to
allow for incorporation of other data.
Many-to-many tables representing the relationships
between the various entities are omitted in the interest
of brevity. However, all of the relationships shown in 1
are also represented in RDBMS.
Export into RDBMS system
The export process is done in four major steps:
1. First, we initialize the rxcui and rxnorm tables.
This includes mapping every deprecated RXCUI toTable 3 The associated RxNorm entity type for each DrOn
entity except disposition





NDC SCD or SBD attributethe most recent RXCUI that identifies the same
object, either to an RXCUI from the current set or
another deprecated, but not entered in error,
RXCUI.
2. Next, we initialize the ndc table. This primarily
involves copying all the NDCs found in the
extraction process (without the duplication caused
by storing NDCs multiple times during the
process) and associating them with the relevant
RXCUI.
3. Next, we create the ingredients, CDFs, CDs, and
BDs from the associated RxNorm type. This
includes maintaining the proper relationships
between the various entities (e.g. associating the
correct ingredients with each CDF).
4. Finally, we associate each NDC with the appropriate
CD or BD. This primarily involves following the
provenance trail of RXCUIs provided in step.
Creating the OWL 2.0 Artifact
We use the OWLAPI 3.4.3 [11], Scala 2.10 [12], and
Slick 1.0.0 [13] to extract the entities from our internal
representation and transform them into an OWL
artifact. This process is subdivided into the following
steps:
1. Extract the ingredients, using ChEBI URIs where
appropriate.
2. Extract the dispositions and associate them via
the bearer_of relation to the one or more
ingredients.
3. Extract the clinical drug forms and associate them
via the has_proper_part relation to the one or more
ingredients.
4. Extract the clinical drugs and assert they are a
subclass of the appropriate clinical drug form.
5. Extract the branded drugs and assert that they are a
subclass of the appropriate clinical drug.
6. Extract the NDCs and assert that they are related to
one branded drug or one clinical drug via the
has_proper_part relation.
This ordering of the steps is deliberate. Each step de-
pends on one or more previous steps.
Since the RDBMS structure defined above represents
the entities and their relationships already, this process
is fairly straightforward.
Results and discussion
We developed an ontology, DrOn, that contains infor-
mation programmatically derived from three different
sources (RxNorm, ChEBI, and PRO) during its build
process. Because it is derived from general-purpose re-
sources, we believe DrOn can serve many use cases
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quires further research). We plan on adding additional
sources in the future to maintain current information in
DrOn, with more immediate plans to include informa-
tion from Structured Product Labels [14]. As such, we
built our internal representation to maintain provenance
information of the sources separately, ensuring that we
can both track the provenance of the various entities as
the ontology develops and add new sources without ad-
versely affecting the existing ontology.
DrOn follows OBO Foundry guidelines and is cur-
rently listed on the OBO Foundry website as a candidate
ontology. In additional to the information from RxNorm
detailed above, DrOn imports BFO 1.1 and includes
terms MIREOTed from the Relationship Ontology, the
Ontology of Biomedical Investigations, and BFO 2.
DrOn contains a total of 514,268 classes as of this
writing. Of these, 2 are MIREOTed, 51 were imported
using OWL’s built in mechanisms, 1,885 were taken
from ChEBI, two were taken from PRO, and the
remaining 512,328 were mined from RxNorm.
The development site and issue tracker for DrOn can
be found at https://bitbucket.org/uamsdbmi/dron. The
permanent URL for DrOn is http://purl.obolibrary.org/
obo/dron.owl. DrOn can also be found in Ontobee [15].
It can be browsed and queried at http://www.ontobee.
org/browser/index.php?o=DRON.
The upper module of DrOn
DrOn is primarily made up of classes created by extract-
ing information from other sources. However, there are
a number of classes that were defined specifically for
DrOn, which we use to give structure to the extracted
data, as well as to handle future work such as represent-
ing dose forms.
We define ‘drug product’ as ‘a material entity (1) con-
taining at least one scattered molecular aggregate as part
(the active ingredient) and (2) that is the bearer of a clin-
ical drug role’. It is currently the superclass to all CDFs
(and thus, all CDs and BDs).
Additionally, we define in DrOn several different sub-
types of drug product, such as ‘drug capsule’ and ‘drug
tablet’. Currently, we do not use these subclasses, but
we will eventually place all the drug products under
them to achieve a better mid-level structure.
As stated above, we imported the ‘processed material’
class from the OBI. OBI defines it as ‘a material entity
that is created or changed during material processing’. It
is the parent class of all the drug ingredients that we
could not match to a ChEBI class (and thus are not
found within the ChEBI structure). Given that most of
these ingredients are plant extracts created by some
form of processing a plant, it was the most appropriate
choice for the time being.The ‘packaged drug product’ class is the superclass of
all of the classes that correspond with NDCs, and thus
one of the primary interfaces between the dron-rxnorm
module and the dron-upper module. At present,
RxNorm contains insufficient information to add struc-
ture to what is essentially a flat list of NDC classes
underneath packaged drug product. However, in the fu-
ture, we anticipate using information from Structured
Product Labels to capture things in bottles vs. boxes, for
example, and adding that level of structure underneath
packaged drug product.
Modularization
The ability to incorporate additional sources of informa-
tion has been a key requirement for the build process.
To help facilitate this ability, we developed DrOn in a
modular fashion. Currently, DrOn has five different
modules: dron-full, dron-chebi, dron-rxnorm, dron-
pro, and dron-upper. Figure 4 illustrates the relation-
ships of these modules to key classes in DrOn.
The dron-full module is simply a connector that im-
ports the other modules. It is so named on the assump-
tion that certain subsets of the modules may prove
useful enough to warrant lighter versions of the
ontology.
The dron-chebi module contains all of the annota-
tions for the ingredients mapped to ChEBI (as described
in the section entitled Mapping to ChEBI). It also con-
tains all of the ChEBI superclasses of the ingredients and
their upper level is-a structure in ChEBI.
The dron-rxnorm module contains all of the informa-
tion mined from RxNorm, which at this point of the
ontology’s development, is the bulk of DrOn’s informa-
tion. It includes the NDCs, though we plan to split the
NDCs from the rest of the RxNorm module in future
work.
The dron-pro module includes everything imported
from the Protein Ontology (PRO). At present, it is very
small and only contains the ‘protein’ and ‘somatotropin’
classes from PRO. As stated above, we imported these
classes to represent somatotropin as a drug ingredient,
which previously was erroneously mapped to a role in
ChEBI.
The dron-upper module contains the hand-curated
upper-level ontology onto which the other modules are
mapped [8].
This modularization brings two major benefits: devel-
opment simplicity and increased scalability. By creating
logical divisions and well-defined interfaces between the
modules, we can more easily maintain each module sep-
arately without significantly affecting the other modules.
Additionally, as each module grows in size, we can dis-
tribute the processing and creation of the ontologies to
different servers, making it simpler to scale the process.
Figure 4 DrOn Infrastructure. The relationship of DrOn modules to key DrOn classes.
Table 4 Several ingredients and ingredient dispositions
and the number of NCDs found associated with them in
DrOn
Ingredient or disposition Number of NDCs
Acetaminophen 19,399
Ibuprofen 5,774
function-inhibiting L-type voltage-gated calcium
channel binding disposition
9,650
function-inhibiting vitamin K epoxide reductase
binding disposition
1,893
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We validated the design of DrOn by building a web-
based software application that supports our primary,
driving use case. This use case was to enable
comparative-effectiveness research at the University of
Arkansas for Medical Sciences, where researchers
wish to study pharmacy claims datasets. To do so,
they need to pull all claims where the drug product
dispensed meets certain criteria. For example, author
WRH was part of a research team wherein a student
had to manually identify all drug products that con-
tain acetaminophen. We built a web application that
uses DrOn to support this use case; users can search
for all NDCs that either contain a specific ingredient
or contain an ingredient that has a specific dispos-
ition (such as beta-adrenergic receptor blockade). This
web application is accessible at http://ingarden.uams.
edu/ingredients.
Using this application, a user can find nearly 20,000
different packaged drug products that contain acet-
aminophen. Table 4 shows a number of ingredients or
ingredient dispositions along with the number of
NCDs the application finds associated with them by
querying DrOn. In previous work [8], we used this
application to test the results of a manually created
list of acetaminophen NDCs against the NDCs found
in DrOn. We found that DrOn contained every NDC
found in the manually curated list.Future work
Future work includes addressing limitations in the
current process. One of the more egregious examples is
the lack of a link from the various drug products to their
dose forms (e.g., drug capsule). Nearly all of the most
common dose forms are already in the upper level of the
ontology (dron-upper module), but the CDFs are not
properly related to them. This is due to (1) time con-
straints and (2) the dubious ontological nature of some
of the dose forms found in RxNorm. For example, ‘in-
haler’ does not refer to the form of the drug but instead
to its container (which also serves the role of drug deliv-
ery device). But the form of the drug itself is a solution
or suspension contained in the inhaler. Note that the
presentation form in this case (e.g., solution) differs from
the administration form (e.g., aerosol).
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some of the terms. For instance, only a small subset of
the parts of each drug product is defined. A CDF has in-
formation about its dose form, its route of administra-
tion, and its active ingredients. As of the writing of this
paper, only active ingredients are represented in the
ontology, though dose forms are mostly represented.
Even these, however, are still not fully developed, gener-
ally lacking class restrictions.
The final issue with the process is the need for manual
interaction. Although each step in the process is auto-
mated, they are not tied together in a coherent way. We
expect that some manual intervention will always be
needed as we continue to mine updated information
from these sources, but there is significant room for im-
provement in connecting the various segments of the
overall process flow and fully automating the less onto-
logically nebulous steps.
Since DrOn is already large and will likely increase in
size as we incorporate more sources and as more drug
products are manufactured, we expect that we will run
into difficulties managing generation of, and reasoning
over, the ontology. One potential solution we intend to
investigate is to reason over modules individually and
combine the results. We also intend to create more
manageable subsets of DrOn, which should allow users
to work with only the portions of DrOn that they need
for a particular use case.
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